How Should Pumicort Be Used?

Pulmicort Respules is a kind of western medicine, which has relatively large side effects on the human body. It should be taken according to the dosage and should not be taken in excess. This medicine can be used to treat bronchial asthma. Pulmicort Respules can replace and reduce the treatment of oral steroids. Pulmicort Respules is not suitable for rapid treatment of bronchospasm. This medicine cannot be used alone to treat persistent asthma or acute asthmatic attacks. How to use Pulmicort Respules? Let's take a look at it next.

Pulmicort Respules is a prescription western medicine. Clinically, this drug is mainly used to treat bronchial asthma. It can replace or reduce the treatment of oral steroids. When the administration of steroids is not suitable, inhaled budesonide suspension can be used. This medicine needs to be administered through a suitable nebulizer. Depending on the nebulizer, the actual inhaled dose for the patient is 40%-60% of the labeled amount. The adult dose is 1-2 mg once a day, and the child dose is 0.5-1 mg once a day, both taken twice a day.

Treatment of bronchial asthma. Can replace or reduce oral steroid therapy. It is recommended to use inhaled budesonide suspension when other methods of steroid therapy are not suitable.

1. Budesonide is not suitable for rapid relief of bronchospasm. Therefore, budesonide should not be used alone to treat persistent asthma or other acute asthmatic attacks, which require strengthened treatment measures.

2. Special caution is required for patients who switch from oral steroids to budesonide treatment, as it takes several months for the hypothalamic-pituitary-adrenal axis to fully recover. During asthma exacerbation or severe attacks, patients may require additional oral steroids. It is recommended that these patients carry a warning card (see Clinical Management: Patients Dependent on Oral Corticosteroids).

3. Patients who have previously received high-dose systemic corticosteroid therapy may experience early recurrence of allergic symptoms, such as rhinitis and eczema, when switching from oral therapy to budesonide therapy due to budesonide's lower systemic corticosteroid effect (see Clinical Management: Patients Dependent on Oral Corticosteroids).

4. High-dose glucocorticosteroids may mask symptoms of existing infections or cause new infections. Special caution is required for patients with active or latent tuberculosis or fungal, bacterial, or viral infections of the respiratory system.

5. Since some patients have shown a certain degree of adrenal cortical function suppression during long-term high-dose treatment, it is recommended to monitor hematology and adrenal function.

6. Administration through positive pressure delivery systems (such as IPPB) is not recommended in the presence of pneumothorax, pneumatocele, or pneumomediastinum, unless special drainage has been performed.

7. Concurrent use of ketoconazole, itraconazole, or other potent CYP3A4 inhibitors should be avoided. If concurrent use of these drugs is necessary, the interval between administrations should be as long as possible.

8. Special attention should be paid when patients who are receiving oral corticosteroids switch to this medicine, as they may be at risk of adrenal cortical insufficiency for a considerable period of time. Patients who require high-dose corticosteroids for emergency treatment and patients who have been receiving the maximum recommended dose of inhaled corticosteroids for a long time may also be at risk of adrenal cortical insufficiency. These patients may manifest symptoms and signs of adrenal cortical insufficiency during periods of severe stress. During periods of stress or elective surgery, systemic corticosteroids should be administered.